by ComplianceQuest

Inspection Tracker

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

FDA Guidance Global Templates

Start with a Free ConsultationBook 30 minutes with a ComplianceQuest specialist.Book a Call

Sign In Create a Free Account

Big News: FDA is moving from MasterControl to ComplianceQuest.See Why

Search AgentQ/

Talk to a Specialist

Loading…

My DashboardInspection TrackerWarning LettersNexlife Inc. dba Nexlife

All Warning Letters

Nexlife Inc. dba Nexlife

Warning LetterOpen

260 Newport Center Dr. Newport Beach , CA 92660 United StatesIssued Jun 8, 2026Center for Drug Evaluation and Research (CDER)

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations1

Issue DateJun 8, 2026

Product TypeDrugs

StatusOpen

Letter Details

Firm: Nexlife Inc. dba Nexlife
Location: 260 Newport Center Dr. Newport Beach , CA 92660 United States
FEI Number: N/A
Country: United States
Issue Date: June 08, 2026
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Subject

False & Misleading Claims/Misbranded (Telehealth)

Nexlife Inc. dba Nexlife FDA Warning Letter, June 8, 2026